ARMATA PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Increase (Decrease) in Accrued Liabilities of $482.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2019-05-06
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-03-31 was $482.00K.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-03-31 was -$355.00K.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2017-09-30 was $73.00K, a 47.86% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2017-06-30 was $188.00K, a 172.46% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2016 was $167.00K, a 3.21% decline from fiscal 2015.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2015 was $172.54K, a 68.91% decline from fiscal 2014.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2014 was $555.00K.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2013 was $0.00.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2019-03-31 | $482.00K 10-Q · filed 2019-05-06 | ||||||
| 2018-03-31 | -$355.00K 10-Q · filed 2019-05-06 | ||||||
| 2017-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $261.00K derived: sum of 2 quarters · filed 2017-11-14 | $250.00K 10-Q · filed 2017-11-14 | $449.00K derived: sum of 4 quarters · filed 2017-11-14 | |||
| 2017-06-30 | $188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $177.00K 10-Q · filed 2017-08-14 | $376.00K derived: sum of 3 quarters · filed 2017-08-14 | $516.00K derived: sum of 4 quarters · filed 2017-11-14 | |||
| 2017-03-31 | -$11.00K 10-Q · filed 2017-05-15 | $188.00K derived: sum of 2 quarters · filed 2017-05-15 | $328.00K derived: sum of 3 quarters · filed 2017-11-14 | $397.00K derived: sum of 4 quarters · filed 2017-11-14 | |||
| 2016-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | $339.00K derived: sum of 2 quarters · filed 2017-11-14 | $408.00K derived: sum of 3 quarters · filed 2017-11-14 | $167.00K 10-K · filed 2017-03-27 | |||
| 2016-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $209.00K derived: sum of 2 quarters · filed 2017-11-14 | -$32.00K 10-Q · filed 2017-11-14 | -$298.00K 10-Q · filed 2016-11-10 | $204.54K derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$172.00K 10-Q · filed 2017-08-14 | -$236.00K 10-Q · filed 2016-08-15 | $64.54K derived: sum of 3 quarters · filed 2017-08-14 | $234.54K derived: sum of 4 quarters · filed 2017-08-14 | ||
| 2016-03-31 | -$241.00K 10-Q · filed 2017-05-15 | -$170.00K 10-Q · filed 2016-05-12 | -$4.46K derived: sum of 2 quarters · filed 2017-05-15 | $165.54K derived: sum of 3 quarters · filed 2017-05-15 | $53.54K derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | $236.54K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | $406.54K derived: sum of 2 quarters · filed 2017-03-27 | $294.54K derived: sum of 3 quarters · filed 2017-03-27 | $172.54K 10-K · filed 2017-03-27 | |||
| 2015-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $58.00K derived: sum of 2 quarters · filed 2016-11-10 | -$64.00K 10-Q · filed 2016-11-10 | -$168.00K derived: sum of 4 quarters · filed 2016-11-10 | |||
| 2015-06-30 | -$112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$234.00K 10-Q · filed 2016-08-15 | -$338.00K derived: sum of 3 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | -$122.00K 10-Q · filed 2016-05-12 | -$226.00K derived: sum of 2 quarters · filed 2016-05-12 | |||||
| 2014-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-15 | $555.00K 10-K · filed 2015-04-15 | |||||
| 2014-09-30 | $659.00K 10-Q · filed 2015-11-16 | ||||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-15 | $0.00 derived: sum of 2 quarters · filed 2015-05-15 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-04-15 | $0.00 10-K · filed 2015-04-15 | |||||
| 2013-09-30 | $0.00 10-Q/A · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |